Almost 70% of BC cases are characterized by estrogen receptor (ER) positivity making these patients eligible for endocrine therapy including selective modulators of estrogen receptors (SERMs), selective estrogen receptor degrader (SERD) fulvestrant, and aromatase inhibitors (AIs). Here, ESR1 is linked to breast cancer.